The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)
Open accessAbstract
BACKGROUND: Treatment of invasive mold infection in immunocompromised patients remains challenging. Voriconazole has been shown to have efficacy and survival benefits over amphotericin B deoxycholate, but its utility is limited by drug interactions. Liposomal amphotericin B achieves maximum plasma levels at a dosage of 10 mg/kg per day, but clinical efficacy data for higher doses are lacking. METHODS: In a double-blind trial, patients with proven or probable invasive mold infection were randomized to receive liposomal amphotericin B at either 3 or 10 mg/kg per day for 14 days, followed by 3 mg/kg per day. The primary end point was favorable (i.e., complete or partial) response at the end of study drug treatment. Survival and safety outcomes were also evaluated. RESULTS: Of 201 patients with confirmed invasive mold infection, 107 received the 3-mg/kg daily dose, and 94 received the 10-mg/kg daily dose. Invasive aspergillosis accounted for 97% of cases. Hematological malignancies were present in 93% of patients, and 73% of patients were neutropenic at baseline. A favorable response was achieved in 50% and 46% of patients in the 3- and 10-mg/kg groups, respectively (difference, 4%; 95% confidence interval, -10% to 18%; P>.05); the respective survival rates at 12 weeks were 72% and 59% (difference, 13%; 95% confidence interval, -0.2% to 26%; P>.05). Significantly higher rates of nephrotoxicity and hypokalemia were seen in the high-dose group. CONCLUSIONS: In highly immunocompromised patients, the effectiveness of 3 mg/kg of liposomal amphotericin B per day as first-line therapy for invasive aspergillosis is demonstrated, with a response rate of 50% and a 12-week survival rate of 72%. The regimen of 10 mg/kg per day demonstrated no additional benefit and higher rates of nephrotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Self-citationAscioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Self-citationEpidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
Marr, K. A., Carter, R. A., Crippa, F., Wald, A., & Corey, L. (2002) · Clinical Infectious Diseases · doi:10.1086/339202 · Cited by 1,448
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979
Walsh, T. J., Teppler, H., Donowitz, G. R., Maertens, J. A., Baden, L. R., Dmoszynska, A., Cornely, O. A., Bourque, M. R., Lupinacci, R. J., Sable, C. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040446 · Cited by 919
Self-citationVoriconazole: A New Triazole Antifungal Agent
Johnson, L. B., & Kauffman, C. A. (2003) · Clinical Infectious Diseases · doi:10.1086/367933 · Cited by 785
Maertens, J., Raad, I., Petrikkos, G., Boogaerts, M., Selleslag, D., Petersen, F. B., Sable, C. A., Kartsonis, N. A., Ngai, A., Taylor, A., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/423381 · Cited by 658
Self-citationCaillot, D., Couaillier, J.-F., Bernard, A., Casasnovas, O., Denning, D. W., Mannone, L., Lopez, J., Couillault, G., Piard, F., Vagner, O., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.253 · Cited by 587
Aspergillus Infections in Transplant Recipients
Singh, N., & Paterson, D. L. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.44-69.2005 · Cited by 579
Wingard, J. R., White, M. H., Anaissie, E., Raffalli, J., Goodman, J., Arrieta, A., & L Amph/ABLC Collaborative Study Group (2000) · Clinical Infectious Diseases · doi:10.1086/317451 · Cited by 527
Changing patterns and trends in systemic fungal infections
Richardson, M. D. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki218 · Cited by 525
Walsh, T. J., Goodman, J. L., Pappas, P., Bekersky, I., Buell, D. N., Roden, M., Barrett, J., & Anaissie, E. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3487-3496.2001 · Cited by 401
AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience
Adler-Moore, J., & Proffitt, R. T. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.suppl_1.21 · Cited by 339
Leenders, A. C. A. P., Daenen, S., Jansen, R. L. H., Hop, W. C. J., Lowenberg, B., Wijermans, P. W., Cornelissen, J., Herbrecht, R., Lelie, H. V. D., Hoogsteden, H. C., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00944.x · Cited by 319
Self-citationRingden, O., Meunier, F., Tollemar, J., Ricci, P., Tura, S., Kuse, E., Viviani, M. A., Gorin, N. C., Klastersky, J., Fenaux, P., et al. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_b.73 · Cited by 280
Ellis, M., Spence, D., de Pauw, B., Meunier, F., Marinus, A., Collette, L., Sylvester, R., Meis, J., Boogaerts, M., Selleslag, D., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/515033 · Cited by 251
Mills, W., Chopra, R., Linch, D. C., & Goldstone, A. H. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb04825.x · Cited by 171
Ng, T., & Denning, D. W. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430100129015 · Cited by 134
Cordonnier, C., Bresnik, M., & Ebrahimi, R. (2007) · Mycoses · doi:10.1111/j.1439-0507.2007.01362.x · Cited by 28
Self-citationPauw, B. E. D., & Patterson, T. F. (2005) · Clinical Infectious Diseases · doi:10.1086/430919 · Cited by 27
Tollemar, J. G., & Ringdén, O. T. H. (1992) · Clinical Drug Investigation · doi:10.1007/bf03258404 · Cited by 25
Kosmidis, J. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_c.73 · Cited by 9
Cited by
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Self-citationPatterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Self-citationDiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)
Kellum, J. A., Lameire, N., & for the KDIGO AKI Guideline Work Group (2013) · Critical Care · doi:10.1186/cc11454 · Cited by 2,827
Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Self-citationCornely, O. A., Alastruey-Izquierdo, A., Arenz, D., Chen, S. C. A., Dannaoui, E., Hochhegger, B., Hoenigl, M., Jensen, H. E., Lagrou, K., Lewis, R. E., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30312-3 · Cited by 1,820
Self-citation
Metadata
- Authors
- Cornely, O. A., Maertens, J., Bresnik, M., Ebrahimi, R., Ullmann, A. J., Bouza, E., Heussel, C. P., Lortholary, O., Rieger, C., Boehme, A., Aoun, M., Horst, H.-A., Thiebaut, A., Ruhnke, M., Reichert, D., Vianelli, N., Krause, S. W., Olavarria, E., Herbrecht, R., & AmBiLoad Trial Study Group
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-05-15
- Volume
- 44
- Issue
- 10
- Pages
- 1289-1297
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2150824761
- Cited by
- 751
- References
- 23
- FWCI
- 43.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.